During the course of this conference, we will be making certain forward-looking statements. These statements are subject to numerous risks and uncertainties and reflect our current expectations and judgments. Examples of these forward-looking statements include statements relating to our expectations for NUEDEXTA sales and revenue growth, future expense levels, the timing and success of future development of AVP-923 for other indications and the potential approval of NUEDEXTA in new markets.Actual results could vary materially from the results anticipated by these statements. Investors should read the risk factors set forth in the AVANIR’s Form 10-K for the year ended September 20, 2011 and periodic reports filed with Securities and Exchange Commission. With that said, I’d now like to turn the call over to Keith Katkin. Keith? Keith Katkin Thank you, Ian and my thanks to each of you for joining us today. I’ll start today by highlighting the achievement of a number of important milestones on the commercial, clinical and regulatory fronts. First, on the commercial side of the business, I’m delighted to report that we continue to significantly grow NUEDEXTA prescriptions. The number of PBA patients being treated and benefiting from NUEDEXTA has steadily grown each month and I’m very pleased with the continued growth in prescriptions that we are observing. Taking a look at monthly prescription numbers, in October, a total of 4,100 prescriptions were written, of which 2,043 were new prescriptions. In our number, a total of 4,896 prescriptions were written, of which 2,562 were new prescriptions. And for December, a total of 5,630 prescriptions were written, of which 2,894 were new prescriptions. Thus, for the first fiscal quarter of 2012, we had a total of 14,626 prescriptions, of which 7,499 were new prescriptions. This represents a 43% increase in total prescriptions versus the prior quarter. The average prescription size during the quarter was 51 capsules.